Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.

Next Previous
Trial Profile

Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalteparin sodium (Primary)
  • Indications Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BRIDGE

Most Recent Events

  • 19 Mar 2013 Planned number of patients changed from 3626 to 2526 as reported by ClinicalTrials.gov.
  • 17 Jan 2013 Planned end date changed from 1 Jan 2013 to 1 Mar 2015 as reported by ClinicalTrials.gov.
  • 13 Feb 2009 Planned initiation date changed from Dec 2008 to May 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top